Treatment effects of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, on hepatic biomarkers in patients with compensated and decompensated cirrhosis

Conference Reports for NATAP

EASL - European Association
for the Study of the Liver
Barcelona, Spain
May 27-30, 2026


Treatment effects of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, on hepatic biomarkers in patients with compensated and decompensated cirrhosis

	EASL 2026 May 26-30 Barcelona